Table: Solasia Pharma -2018 group results (IFRS)

Solasia Pharma KK

13/02/2019 06:00

Feb 13 (Reuters)- 
              Solasia Pharma K. K. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   Year ended      Year ended       Year to        NEXT  
                Dec 31, 2018    Dec 31, 2017   Dec 31, 2019      YEAR    
                   LATEST         YEAR-AGO        COMPANY      COMPANY   
                   RESULTS         RESULT        FORECAST    H1 FORECAST 
  Sales            318 mln         410 mln                               
                 (-22.4 pct)     (-18.0 pct)                             
  Operating       loss 2.42       loss 1.01                              
  Pretax          loss 2.45       loss 1.02                              
  Net             loss 2.42       loss 1.01                              
  EPS Basic    loss 25.98 yen  loss 12.24 yen                            
  EPS Diluted  loss 25.98 yen  loss 12.24 yen                            
  Ann Div            NIL             NIL            NIL                  
  -Q2 Div            NIL             NIL            NIL                  
  -Q4 Div            NIL             NIL            NIL                  
 
  NOTE - Solasia Pharma K. K.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T